id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2015-E-3316-0006,FDA,FDA-2015-E-3316,Determination of Regulatory Review Periods for Purposes of Patent Extension: ADVANTAME,Notice,Determinations,2017-11-30T05:00:00Z,2017,11,2017-11-30T05:00:00Z,2018-01-30T04:59:59Z,2017-11-30T15:57:22Z,2017-25780,0,0,0900006482cc09cd
FDA-2015-E-3316-0007,FDA,FDA-2015-E-3316,Determination of Regulatory Review Periods for Purposes of Patent Extension: ADVANTAME,Notice,Determinations,2017-11-30T05:00:00Z,2017,11,2017-11-30T05:00:00Z,2018-01-30T04:59:59Z,2017-11-30T15:59:10Z,2017-25780,0,0,0900006482cc2a5c
FDA-2015-E-3316-0005,FDA,FDA-2015-E-3316,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2017-07-12T04:00:00Z,2017,7,2017-07-12T04:00:00Z,,2017-07-12T20:51:13Z,,0,0,09000064829144e7
FDA-2015-E-3316-0004,FDA,FDA-2015-E-3316,Letter from U.S. Patent and Trademark Office to FDA,Other,Letter(s),2017-06-01T04:00:00Z,2017,6,2017-06-01T04:00:00Z,,2017-06-01T15:16:32Z,,0,0,090000648267731b